CCDC35 Activators
CCDC35 activators are a class of compounds that enhance the activity of the CCDC35 (coiled-coil domain-containing 35) protein, which is involved in various cellular functions, particularly those related to the cytoskeleton and intracellular organization. CCDC35 is known to contribute to the structural integrity of the cell, helping to coordinate the formation and stability of microtubules and other cytoskeletal elements. Activators of CCDC35 typically work by enhancing the protein's interactions with other cytoskeletal proteins or stabilizing its conformation, thus promoting its role in organizing cellular structures. These compounds help to elucidate how CCDC35 modulates the dynamics of cytoskeletal organization, including processes such as cell division, migration, and intracellular transport.
The mechanism of action for CCDC35 activators often involves binding to allosteric sites on the protein or facilitating interactions between CCDC35 and its cellular partners. By increasing CCDC35 activity, these activators allow for a more robust exploration of its contributions to cellular architecture and mechanical stability. Researchers use CCDC35 activators to study the protein's role in maintaining the cytoskeletal network and how it influences the behavior of cells under various physiological conditions. By modulating CCDC35 activity, these activators help in understanding the broader implications of cytoskeletal regulation in processes like cell shape maintenance, polarity, and intracellular organization, providing insights into how cells maintain their structure and respond to mechanical stimuli.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that binds to and activates beta-adrenergic receptors, causing an increase in intracellular cAMP levels. This activation of the cAMP pathway can lead to the activation of PKA, which may phosphorylate and thereby activate CCDC35. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs), which leads to increased cAMP levels by preventing its breakdown. Higher cAMP levels can activate PKA, which could then lead to the phosphorylation and activation of CCDC35. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) activates its G protein-coupled receptors, which can lead to an increase in cAMP production through adenylyl cyclase activation. This cAMP can then activate PKA, potentially leading to the phosphorylation and activation of CCDC35. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases (SAPKs) like JNK. This kinase activation can lead to the activation of transcription factors and other proteins that may include CCDC35 as a downstream target. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a membrane-permeable cAMP analog that directly activates cAMP-dependent pathways. Upon entering the cell, it activates PKA, which may phosphorylate CCDC35 resulting in its activation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A, which could lead to increased phosphorylation levels of proteins, as their dephosphorylation is inhibited. This can result in the sustained activation of proteins like CCDC35 that are regulated by phosphorylation. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, also known as adrenaline, binds to and activates adrenergic receptors, which increases cAMP production and activates PKA. PKA can then phosphorylate various targets, potentially including CCDC35, resulting in its activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, which degrades cAMP. Inhibition of PDE4 results in increased cAMP levels, leading to PKA activation. PKA could then phosphorylate and activate CCDC35. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of PDE5, which primarily breaks down cGMP but can also influence cAMP levels. Inhibition of PDE5 may result in altered PKA activity, potentially leading to the phosphorylation and activation of CCDC35. | ||||||